Onyee Chan, MD

Articles

Future Direction in CML: Acknowledging Use of Allogeneic Transplant, Key Challenges, and Unmet Needs

September 24th 2025

Panelists discuss the declining role of allogeneic transplant in chronic myeloid leukemia (CML) due to advances in tyrosine kinase inhibitors (TKIs) while emphasizing ongoing challenges related to treatment tolerability, management of advanced disease, and financial toxicity that necessitate continued research and supportive care strategies.

Clinical Approach to Choice of Third-Line TKI in R/R CML

September 24th 2025

Panelists discuss the critical role of mutation testing and individualized ponatinib dosing in managing resistant or relapsed chronic myeloid leukemia (CML), emphasizing frequent molecular monitoring and multidisciplinary care to balance treatment efficacy with toxicity.

Clinical Perspectives: A 45-Year-Old Man With R/R CML

September 24th 2025

Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.

Treatment-Free Remission in CML: Long-Term Monitoring and Care Approach

September 17th 2025

Panelists discuss the importance of monitoring molecular milestones in chronic myeloid leukemia (CML) to guide treatment response and eligibility for treatment-free remission (TFR), emphasizing the multidisciplinary team’s role—including pharmacists and nurses—in supporting adherence, managing adverse effects, and providing individualized patient care.

First-Line TKI Treatment Selection in Newly Diagnosed CML

September 17th 2025

Panelists discuss the evolving landscape of frontline chronic myeloid leukemia (CML) treatment, highlighting asciminib’s emerging role as a preferred first-line therapy due to its favorable efficacy, tolerability, and potential to simplify treatment selection while supporting long-term goals like deep molecular response and treatment-free remission.

Beyond the Prescriber: Integrating the Multidisciplinary Team Into CML Management

September 10th 2025

Panelists discuss the critical role of early molecular testing and multidisciplinary collaboration—including pharmacists, nurse practitioners, and physicians—in personalizing chronic myeloid leukemia (CML) treatment, managing adverse effects, and supporting patient adherence to optimize long-term outcomes.

The CML Patient Journey: A Multidisciplinary Approach to CML Management

September 10th 2025

Panelists discuss a multidisciplinary approach to managing chronic myeloid leukemia (CML), using a clinical case to highlight the importance of early diagnosis, timely referral to specialized centers, and coordinated care among oncologists, nurse practitioners, and pharmacists to optimize patient outcomes.

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

December 24th 2024

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.